Adrenomed
Germany - HennigsdorfBiotechnology
Focus: Adrenomed is a Germany-based biotech focused on sepsis therapeutics, specifically developing adrecizumab for septic shock. The company operates as a public-stage biotech with a singular therapeutic focus in infectious diseases.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Adrenomed
AI assessmentNot HiringNo open roles listed right now. Follow Adrenomed to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
adrecizumab
Septic ShockClinical Trials (3)
NCT03085758Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
Phase 2Help build intelligence for Adrenomed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.